Patrice Nasnas, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an insight into the future of therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), commenting on the development of chemotherapy-free approaches including tyrosine kinase inhibitors (TKIs) and blinatumomab, to decrease the toxicity associated with current standards of care (SOC). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.